NeurogesX to Host Investor Day and Live Webcast on April 30, 2010 in New York City

SAN MATEO, Calif., April 23 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City.

The Investor Day will be webcast live and archived for 30 days on the investor relations section of the NeurogesX website at www.neurogesx.com.

Following the recent U.S. launch of Qutenza® (capsaicin) 8% patch, NeurogesX's senior management will review the commercialization strategy and provide an update on reimbursement. Upcoming research and development activities will also be discussed.

In addition, a physician panel will discuss issues related to the practice of pain medicine, experiences and patient reactions to Qutenza and will also discuss its integration into physician practice for the treatment of postherpetic neuralgia (PHN):

• Dr. Richard Rauck, M.D., a board-certified anesthesiologist, CEO and Medical Director of the Carolinas Pain Institute and Clinical Associate Professor at Wake Forest University Health Sciences
• Dr. David Simpson, M.D., a Professor of Neurology at Mount Sinai School of Medicine, Director of the Clinical Neurophysiology Laboratories and Director of the Neuro-AIDS Program at Mount Sinai Hospital
• Dr. Lynn Webster, M.D., F.A.C.P.M., F.A.S.A.M., cofounder and medical director of Lifetree Clinical Research who is board certified in anesthesiology and pain management

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza® (capsaicin) 8% patch, is a localized dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies.

The Company's early-stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza® and its benefits and potential duration of effect.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to manufacture and supply of Qutenza; Qutenza and NeurogesX's other product candidates may have unexpected adverse side effects; and physician or patient reluctance to use Qutenza. For further information regarding these and other risks related to NeurogesX's business, investors should consult NeurogesX's filings with the Securities and Exchange Commission.

SOURCE NeurogesX, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED